Broekmans, Marloes E.C.
88  results:
Search for persons X
?
4

Functional MYCN signature predicts outcome of neuroblastoma..:

Valentijn, Linda J. ; Koster, Jan ; Haneveld, Franciska...
Proceedings of the National Academy of Sciences.  109 (2012)  47 - p. 19190-19195 , 2012
 
?
5

Functional MYCN signature predicts outcome of neuroblastoma..:

Valentijn, Linda J. ; Koster, Jan ; Haneveld, Franciska...
Proceedings of the National Academy of Sciences of the United States of America.  109 (2012)  47 - p. 19190-19195 , 2012
 
?
7

NK Cell Phenotype Is Associated With Response and Resistanc..:

Verkleij, Christie P.M ; Frerichs, Kristine A ; Broekmans, Marloes E.C...
https://research.rug.nl/en/publications/f4115bfc-b10e-4728-8dbf-d87f2c59db7e.  , 2023
 
?
9

Preclinical activity and determinants of response of the GP..:

Verkleij, Christie P. M ; Broekmans, Marloes E. C ; van Duin, Mark...
Verkleij , C P M , Broekmans , M E C , van Duin , M , Frerichs , K A , Kuiper , R , de Jonge , A V , Kaiser , M , Morgan , G , Axel , A , Boominathan , R , Sendecki , J , Wong , A , Verona , R I , Sonneveld , P , Zweegman , S , Adams , H C , Mutis , T & van de Donk , N W C J 2021 , ' Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma ' , Blood , vol. 5 , no. 8 , pp. 2196-2215 . https://doi.org/10.1182/BLOODADVANCES.2020003805.  , 2021
 
?
11

Preclinical Activity of JNJ-7957, a Novel BCMA ×CD3 Bispeci..:

Frerichs, Kristine A ; Broekmans, Marloes E. C ; Marin Soto, Jhon A...
Frerichs , K A , Broekmans , M E C , Marin Soto , J A , van Kessel , B , Heymans , M W , Holthof , L C , Verkleij , C P M , Boominathan , R , Vaidya , B , Sendecki , J , Axel , A , Gaudet , F , Pillarisetti , K , Zweegman , S , Adams , H C , Mutis , T , van de Donk , N W C J & van de Donk , N W C J 2020 , ' Preclinical Activity of JNJ-7957, a Novel BCMA ×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab ' , Clinical cancer research : an official journal of the American Association for Cancer Research , vol. 26 , no. 9 , pp. 2203-2215 . https://doi.org/10.1158/1078-0432.CCR-19-2299.  , 2020
 
?
12

Preclinical rationale for targeting the PD‐1/PD‐L1 axis in ..:

Verkleij, Christie P.M ; Jhatakia, Amy ; Broekmans, Marloes E.C...
Verkleij , C P M , Jhatakia , A , Broekmans , M E C , Frerichs , K A , Zweegman , S , Mutis , T , Bezman , N A & van de Donk , N W C J 2020 , ' Preclinical rationale for targeting the PD‐1/PD‐L1 axis in combination with a CD38 antibody in multiple myeloma and other CD38‐ positive malignancies ' , Cancers , vol. 12 , no. 12 , 3713 , pp. 1-20 . https://doi.org/10.3390/cancers12123713.  , 2020
 
1-15